Cargando…

Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer

Neoadjuvant chemotherapy (NACT) has been established as being an effective treatment for advanced gastric cancer (GC), while the predictive biomarker of NACT efficacy remains under investigation. Aspartate β-hydroxylase (ASPH) represents an attractive target which is a highly conserved transmembrane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gan, Xuejun, Li, Shen, Wang, Yiding, Du, Hong, Hu, Ying, Xing, Xiaofang, Cheng, Xiaojing, Yan, Yan, Li, Ziyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053938/ https://www.ncbi.nlm.nih.gov/pubmed/36982561 http://dx.doi.org/10.3390/ijms24065482

Ejemplares similares

LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S-1
por: Yang, Fang, et al.
Publicado: (2021)

Clinical Significance and Immune Infiltration Analyses of the Cuproptosis-Related Human Copper Proteome in Gastric Cancer
por: Tang, Xiaohuan, et al.
Publicado: (2022)

miR-638 Serves as a Biomarker of 5-Fluorouracil Sensitivity to Neoadjuvant Chemotherapy in Breast Cancer
por: Wang, Bin, et al.
Publicado: (2022)

Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis
por: Xing, Xiaofang, et al.
Publicado: (2022)

Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: Wang, Yinkui, et al.
Publicado: (2020)

D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy
por: Go, Se-Il, et al.
Publicado: (2015)

Identification of Immunogenic Cell-Death-Related Subtypes and Development of a Prognostic Signature in Gastric Cancer
por: Gan, Xuejun, et al.
Publicado: (2023)

TEADs serve as potential prognostic biomarkers and targets for human gastric cancer
por: Wang, Meng-huan, et al.
Publicado: (2022)

NEK2 serves as a prognostic biomarker for hepatocellular carcinoma
por: Li, Gang, et al.
Publicado: (2017)

Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients
por: Feng, Dechao, et al.
Publicado: (2023)

Diverse molecular functions of aspartate β-hydroxylase in cancer
por: Zheng, Wenqian, et al.
Publicado: (2020)

Aspartate β-hydroxylase as a target for cancer therapy
por: Kanwal, Madiha, et al.
Publicado: (2020)

Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Liu, Zining, et al.
Publicado: (2021)

Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy
por: Gensthaler, Lisa, et al.
Publicado: (2023)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Case report: anaesthetic management of radical gastrectomy for gastric cancer associated with anti-N-methyl-D-aspartate receptor encephalitis
por: Ding, Lei, et al.
Publicado: (2017)

Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma
por: Sun, Shiquan, et al.
Publicado: (2023)

Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer
por: Tang, Xiaohuan, et al.
Publicado: (2022)

AGT May Serve as a Prognostic Biomarker and Correlated with Immune Infiltration in Gastric Cancer
por: Wu, Fanqi, et al.
Publicado: (2022)

Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer
por: Li, Shen, et al.
Publicado: (2015)

Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy
por: Li, Ziyu, et al.
Publicado: (2020)

Integrin-β6 Serves as a Potential Prognostic Serum Biomarker for Gastric Cancer
por: Li, Zequn, et al.
Publicado: (2021)

Aberrant upregulation of 14-3-3ơ expression serves as an inferior prognostic biomarker for gastric cancer
por: Zhou, Wei-hua, et al.
Publicado: (2011)

Circulating miR-326 could serve as a predictive biomarker for response to neoadjuvant chemotherapy in locally advanced cervical cancer
por: Zou, Kangni, et al.
Publicado: (2022)

ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients
por: Li, Ziyu, et al.
Publicado: (2016)

ITGA3 serves as a diagnostic and prognostic biomarker for pancreatic cancer
por: Jiao, Yan, et al.
Publicado: (2019)

GPSM2 Serves as an Independent Prognostic Biomarker for Liver Cancer Survival
por: Yang, Dingquan, et al.
Publicado: (2020)

Aspartate β-hydroxylase expression promotes a malignant pancreatic cellular phenotype
por: Dong, Xiaoqun, et al.
Publicado: (2014)

Aspartate β-hydroxylase disrupts mitochondrial DNA stability and function in hepatocellular carcinoma
por: Tang, C, et al.
Publicado: (2017)

MicroRNA hsa-mir-3923 serves as a diagnostic and prognostic biomarker for gastric carcinoma
por: Yang, Xiaohui, et al.
Publicado: (2020)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy
por: Khandakar, Binny, et al.
Publicado: (2014)

Characterization of the Relationship Between the Expression of Aspartate β-Hydroxylase and the Pathological Characteristics of Breast Cancer
por: Zhang, Yanan, et al.
Publicado: (2020)

Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer
por: CUI, HAI-BIN, et al.
Publicado: (2014)

Correction: Aspartate β-hydroxylase expression promotes a malignant pancreatic cellular phenotype
por: Dong, Xiaoqun, et al.
Publicado: (2019)

Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment
por: Liu, Zining, et al.
Publicado: (2021)

Correlative Analysis Between Adverse Events of Preoperative Chemotherapy and Postoperative Complications of Gastric Cancer
por: Wu, Zhouqiao, et al.
Publicado: (2021)

G-rich sequence factor 1 serves as a prognostic biomarker in septic patients
por: Qi, Lei, et al.
Publicado: (2021)

Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer
por: Wang, Guangjun, et al.
Publicado: (2023)

Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer
por: Sandø, Alina Desiree, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v4mei5s404k1rve4v9dhcdfnkk